Recently, a groundbreaking global clinical trial for an rAAV gene therapy targeting sarcopenia has been initiated at West China Hospital, Sichuan University. Titled "A clinical study to evaluate the safety and efficacy of ZS112 injection in the treatment of sarcopenia patients," this trial marks a significant advancement in medical research. The successful treatment of the first patient sets the stage for potential transformative outcomes in the field of sarcopenia therapy.

The project was launched by a team of principal investigators, including Director Birong Dong and Director Jirong Yue from the National Clinical Research Center for Geriatric Diseases at West China Hospital, Sichuan University, as well as Director Chengqi He and Associate Director Qian Wang from the Rehabilitation Center. The drug, ZS112 injection, was originally developed by Sichuan Real & Best Biotechnology Co., Ltd. The first subject underwent gene therapy and completed the initial follow-up. At present, the subject is in good condition, and the therapeutic gene is correctly expressed, demonstrating the safety and efficacy of the ZS112 drug. This marks a critical transition of the ZS112 project from basic laboratory research results to clinical application, bringing new hope to patients with sarcopenia.

As of January 31, 2024, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has announced that Sichuan Real&Best Biotechnology Co., Ltd.'s groundbreaking Fabry disease gene therapy product ZS805 injection has received implied approval for clinical trials and is about to embark on Phase I/II clinical trials. This marks a significant milestone as Real&Best becomes the first domestic pharmaceutical company to gain clinical approval for an original gene therapy drug for Fabry disease.